SCHEMBL5539439

SCHEMBL5539439

C=CCCCCc1ccccc1[O]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
TLR8 Q9NR97 1/20 0.41
LMNA P02545 2/20 0.39
EP300 Q09472 1/20 0.38
KAT2B Q92831 1/20 0.38
KAT5 Q92993 1/20 0.38
KAT8 Q9H7Z6 1/20 0.38
HDAC1 Q13547 2/20 0.36
THRA P10827 1/20 0.36
THRB P10828 1/20 0.36
HDAC4 P56524 1/20 0.36
MAPT P10636 2/20 0.31
ABCC4 O15439 1/20 0.31
BID P55957 3/20 0.31
BCL2L1 Q07817 3/20 0.31
MCL1 Q07820 3/20 0.31
BAK1 Q16611 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538657 0.94 TLR8 (0.45) TDP1USP2ALDH1A1HPGDTLR8
SCHEMBL5543571 0.86 TLR8 (0.33) TDP1USP2ALDH1A1HPGDTLR8
SCHEMBL8076094 0.81 ALDH1A1 (0.43) TDP1USP2ALDH1A1HPGDTLR8
SCHEMBL8076164 0.79 USP2 (0.46) TDP1USP2ALDH1A1HPGDTLR8
SCHEMBL8063272 0.79 USP2 (0.46) TDP1USP2ALDH1A1HPGDTLR8
SCHEMBL8073318 0.79 USP2 (0.46) TDP1USP2ALDH1A1HPGDTLR8
SCHEMBL8062344 0.79 USP2 (0.46) TDP1USP2ALDH1A1HPGDTLR8
SCHEMBL248775 0.77 TAAR1 (0.48) TDP1USP2ALDH1A1HPGDTLR8
SCHEMBL8072160 0.77 TAAR1 (0.50) TDP1USP2ALDH1A1HPGDTLR8
SCHEMBL8073131 0.77 TAAR1 (0.48) TDP1USP2ALDH1A1HPGDTLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TDP1 4666/4885USP2 3074/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.